WO2007085681A1

WO2007085681A1 - Treatment substance containing magnesium salts for treatment of tumors or like and use of magnesium salts

Info

Publication number: WO2007085681A1
Application number: PCT/FI2006/000394
Authority: WO
Inventors: Kari Honkanen
Original assignee: Medgenerics Oy
Priority date: 2006-01-24
Filing date: 2006-11-29
Publication date: 2007-08-02
Also published as: EP1976540A4; EP1976540A1; FI20060065A; FI20060065A0; FI119101B

Abstract

The invention relates on the one hand to a treatment substance containing magnesium salts for the treatment of tumors or the like and, on the other hand, to a novel use of magnesium sulfate. The treatment substance, used particularly for removing warts internally, is based, as regards its active ingredient, essentially on magnesium sulfate, the treatment substance being formulated for anal administration, such as in the form of a suppository or the like.

Description

Treatment substance containing magnesium salts for treatment of tumors or like and use of magnesium sulfate

The invention relates on the one hand to a treatment substance containing magnesium salts for the treatment of tumors or the like, the treatment substance, used particularly for removing warts internally, being based, as regards its active ingredient, essentially on magnesium sulfate, and on the other hand to a novel use of magnesium sulfate.

Warts (Verruca vulgaris) are tumor-like changes in the skin and believed to be caused especially by Papilloma virus. Warts may appear in various parts of the body, but mostly in the hands and feet. School children are particularly susceptible to developing warts, becoming exposed in their gymnastic/exercise activities, swimming pools, shower facilities, etc.

At present, warts are most commonly attended locally, e.g. by means of salicylic-acid containing bandaids and solutions, deep freezing, laser, surgery or electric needle treatments . The foregoing type of therapies usually necessitate the individual treatment of each wart, as a result of which a plurality of treatments are occasionally necessary, depending on the type of therapy and the number of warts. Further, especially when applying e.g. an acid treatment or surgical procedures, the results involve practically always cosmetic flaws, necessitating a meticulous postoperative care to avoid infections and to achieve a full recovery of the skin following a wart removal . The current treatments of warts often involve not only cosmetic flaws but also outright pains. In the event that warts develop in abundance, the above type of treatments become impossible to conduct in a single session but, instead, the removal of warts must be sequenced over a longer period of time unless the warts disappear by themselves after starting the removal process.

Magnesium-containing products, as such, have been used in various therapies, e.g. as antacids, laxative and purgative preparations, but also as anticonvulsants and sedatives .

On the other hand, especially the published international patent application WO95/31991 proposes particularly the use of magnesium ions, especially magnesium pyrofosfate, in combination with vitamins B6 for the prophylaxis of neoplastic and autoimmune diseases. For example, with a daily dosage of up to 368 g of magnesium sulfate per kg of a patient's body weight, a discernible recovery has been observed in the form of lesion disappearance and/or the disease indicating less negative activity index values over a period of about 3 to 12 months .

Further, the publication EP 654,270 has claimed that composite preparations, containing magnesium, sodium, calcium, and potassium, are effective, among others, in the treatment of acne, herpes, seborrheic dermatitis and other skin disorders.

Further, the publication DE 19541735 discloses a solution, which is intended for the use of hydrothermal composite preparations, containing not only magnesium but also numerous other ingredients, in the treatment of e.g. skin problems, warts, orange-peel skin, psoriasis, acne, etc., not only by subcutaneous application but also in the form of e.g. bath salts, soaps, lotions, massage oils, sun screens, etc., or else e.g. in the form of tablets or solutions for oral administration. Prior known are also a plurality of magnesium-sulfate containing compositions for internal dosage. Orally administered compositions for removing warts have been described e.g. in the International patent publication WO 99/38517.

Notwithstanding the above solutions, there is no therapy available today that would be sufficiently simple and effective in practice specifically for removing warts in the event that e.g. swallowing problems and stomachaches are caused by magnesium sulfate when administered orally.

The objective in using a treatment substance of the invention, containing magnesium salts, and in using magnesium sulfate is to provide a decisive improvement regarding the above problems and to thereby raise substantially the existing state of the art. In order to accomplish this objective, the features, principally characteristic of a treatment substance of the invention, containing magnesium salts, and of a novel use of magnesium sulfate, are presented in the characterizing clauses of the independent claims directed to two alternative implementations of each of them.

A treatment substance of the invention and a novel application of magnesium sulfate enable a rapid and safe therapy, particularly for the removal of warts by the activity of an internally administered, magnesium-sulfate based treatment substance without a risk of the treatment causing e.g. swallowing, gullet or gastric trouble for a person being attended. The therapy conducted with a treatment substance of the invention provides positive results with extremely slight or totally without side effects over a treatment period which in the best case scenario is less than a week, the treatment resulting in a simultaneous disappearance of warts from the patient's skin, even from various extremities. Because the therapy- enabled, by the invention is based in most cases on per se harmless chemistry with no direct side effects being anticipated, a trouble-free repetition of the therapy, conducted with a treatment substance of the invention, is also possible in the event that warts reoccurring. Thus, a principal benefit offered by the invention lies in the fact that a treatment substance, which lends itself to easy and agreeable internal administration, enables a simultaneous treatment of warts present even in various parts of the body, the warts disappearing by themselves during the course of the treatment with no need for after-care and/or corrective measures of the skin that are usually required in local treatments.

One preferred embodiment of the invention is presented in the dependent claims directed to the use of a treatment substance of the invention and magnesium sulfate.

The invention will be described in more detail in the following specification.

The invention relates first of all to a treatment substance containing magnesium salts for the treatment of tumors or the like, the treatment substance, used particularly for removing warts internally, being based, as regards its active ingredient, essentially on magnesium sulfate. The treatment substance is formulated for anal administration, such as in the form of a suppository or the like. This enables avoiding the problems caused by oral administration of the treatment substance. In a preferred embodiment of the invention, the single dose of magnesium sulfate delivered by the treatment substance is 715-1200, most preferably 950 g, administered three times a day for the period of at least a week.

In an alternative embodiment preferable over what is described above, the treatment substance is formulated for a solution administered as a subcutaneous or submucuous injection. This way, by applying the treatment substance in the immediate vicinity of a wart, it may well be possible to obtain good results by dosages lesser than what is described above, e.g. by injections given in a few successive days, since there is no need to carry the treatment substance in a sufficient dosage over the entire circulation, e.g. in the process of treating a single wart .

On the other hand, the invention relates also to the use of magnesium sulfate by anal administration, such as in the form of a suppository or the like, in the manufacture of a treatment substance used particularly for the removal of warts .

In a further preferred embodiment, the invention relates to the use of magnesium sulfate in the manufacture of a treatment substance, the single dose of magnesium sulfate delivered thereby being 715-1200, most preferably 950 g, administered three times a day for the period of at least a week.

In an embodiment alternative with respect to what is set forth above, the invention enables the use of magnesium sulfate also in the manufacture of a solution for administration as a subcutaneous or submucuous injection, particularly for the removal of warts. The therapy enabled by the invention has been subjected to practical testing, specifically by using a treatment solution with 20 g of magnesium sulfate and 280 ml of purified water . The test group was divided in two, the first faction being treated with a magnesium-sulfate based treatment substance and the second faction with a placebo treatment. In comparison, the therapy was conducted with identical single doses for each group in either one- or two-week long treatment periods, after which it was verifiable that the magnesium-sulfate based therapy provided invariably a good result as all warts in the attended patients disappeared. On the other hand, not a single cure of warts was found in the therapy given as a placebo treatment. When the patients of this second group were thereafter subjected to a therapy based on magnesium sulfate, the healing result was again positive as the warts disappeared in the best case in one and a half weeks.

It is obvious that the invention is not limited to the foregoing embodiments as it can be varied within the same basic concept, e.g. in such a way that the treatment substance includes suitable dyes, excipients and/or additives used as its per se inert ingredients.

Claims

1. A treatment substance containing magnesium salts for the treatment of tumors or the like, the treatment substance, used particularly for removing warts internally, being based, as regards its active ingredient, essentially on magnesium sulfate, characterized in that the treatment substance is formulated for anal administration, such as in the form of a suppository or the like.

2. A treatment substance as set forth in claim 1, characterized in that the single dose of magnesium sulfate delivered thereby is 715-1200, most preferably 950 g, administered three times a day for the period of at least a week.

3. A treatment substance containing magnesium salts for the treatment of tumors or the like, the treatment substance, used particularly for removing warts internally, being based, as regards its active ingredient, essentially on magnesium sulfate, characterized in that the treatment substance is formulated for a solution administered as a subcutaneous or submucuous injection.

4. The use of magnesium sulfate by anal administration, such as in the form of a suppository or the like, in the manufacture of a treatment substance used particularly for the removal of warts .

5. The use of magnesium sulfate according to claim 3 in the manufacture of a treatment substance, the single dose of magnesium sulfate delivered thereby being 715-1200, most preferably 950 g, administered three times a day for the period of at least a week.

6. The use of magnesium sulfate in the manufacture of a solution for administration as a subcutaneous or submucuous injection, particularly for the removal of warts .